February 2027
CFP closes 27 Jan
Global Conference on Aptamer Therapeutics and Molecular Recognition
GCATMR 2027
Global Conference on Aptamer Therapeutics and Molecular Recognition is a one-day event in Manchester, UK on 28 February 2027, organized by iPHARMA Conferences. Abstracts are due by 27 January 2027. iPHARMA Conferences has 151 other upcoming conferences listed here.
Important dates
-
Abstract / full paper deadline
In 72 days
-
Conference
Manchester, UK
All deadlines are as published by the organizer. Check the official website for the time zone.
About this conference
This academic event centers on innovations and research in aptamer therapeutics and molecular recognition, fostering a collaborative environment for scientists, clinicians, and academics. Participants are invited to submit papers, posters, and presentations that discuss recent advancements in aptamer technologies, their applications in drug delivery, and implications for molecular diagnostics. The agenda includes keynote speeches, thematic sessions, and interactive workshops designed to offer practical insights and stimulate dialogue. Designed for professionals seeking to further their understanding and make impactful connections, the conference emphasizes the importance of interdisciplinary collaboration to tackle ongoing challenges in therapeutic applications.
Call for papers
Abstracts are due by 27 January 2027. Submission details are on the official website.
Where this information comes from
- Source
- Submitted by the organizer
- Listed on
- 2 November 2026
- Verification
- Reviewed by an editor before publishing
- Reference
- FCA2923139
Questions about GCATMR 2027
When and where is GCATMR 2027?
28 February 2027 in Manchester, UK.
Can I attend online?
This listing does not confirm an online option. Check the official website.
What is the submission deadline?
Abstracts are due by 27 January 2027.
How do I register?
Registration and fees are handled by the organizer on the official website.
Verify that you represent this event.
Tell us what needs to be reviewed.